SLXN (Silexion Therapeutics) EV-to-EBITDA : -0.32 (As of May. 21, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Silexion Therapeutics's enterprise value is $5.44 Mil. Silexion Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-17.06 Mil. Therefore, Silexion Therapeutics's EV-to-EBITDA for today is -0.32.

The historical rank and industry rank for Silexion Therapeutics's EV-to-EBITDA or its related term are showing as below:

SLXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.32 Med: 0 Max: 0
Current: -0.32

SLXN's EV-to-EBITDA is ranked worse than
100% of 496 companies
in the Biotechnology industry
Industry Median: 7.77 vs SLXN: -0.32

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-21), Silexion Therapeutics's stock price is $0.9042. Silexion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-21.100. Therefore, Silexion Therapeutics's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Silexion Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Silexion Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics EV-to-EBITDA Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EV-to-EBITDA

-0.43

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial					-	-	-0.64	-0.43	-0.40

Competitive Comparison of Silexion Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Silexion Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's EV-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Silexion Therapeutics EV-to-EBITDA Calculation

Silexion Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	5.443	/	-17.057
	=	-0.32

Silexion Therapeutics's current Enterprise Value is $5.44 Mil.
Silexion Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.06 Mil.

Silexion Therapeutics (NAS:SLXN) EV-to-EBITDA Explanation

Silexion Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.9042	/	-21.100
	=	At Loss

Silexion Therapeutics's share price for today is $0.9042.
Silexion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.100.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Silexion Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Abba Hillel Road, Ramat-Gan, ISR, 5250606

Website

https://silexion.com

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.